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Abstract: Parkinson’s Disease (PD) is a complex neurodegenerative disorder classically 
characterized by movement impairment. Pathologically, the most striking features of PD  
are the loss of dopaminergic neurons and the presence of intraneuronal protein inclusions 
primarily composed of alpha-synuclein (-syn) that are known as Lewy bodies and Lewy 
neurites in surviving neurons. Though the mechanisms underlying the progression of PD 
pathology are unclear, accumulating evidence suggests a prion-like spreading of -syn pathology. 
The intracellular homeostasis of -syn requires the proper degradation of the protein by three 
mechanisms: chaperone-mediated autophagy, macroautophagy and ubiquitin-proteasome. 
Impairment of these pathways might drive the system towards an alternative clearance 
mechanism that could involve its release from the cell. This increased release to the extracellular 
space could be the basis for -syn propagation to different brain areas and, ultimately, for the 
spreading of pathology and disease progression. Here, we review the interplay between -syn 
degradation pathways and its intercellular spreading. The understanding of this interplay  
is indispensable for obtaining a better knowledge of the molecular basis of PD and, 
consequently, for the design of novel avenues for therapeutic intervention. 
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1.1. Parkinson’s Disease 
Parkinson’s disease (PD) is the most common neurodegenerative disorder with movement impairment. 
At the clinical level, the disease is classically characterized by resting tremor, bradykinesia, postural 
instability, and muscular rigidity [1]. Although PD was initially classified as a movement disorder,  
it is now well accepted that non-motor symptoms precede and follow motor disabilities. Thus, PD is 
currently regarded as a disorder affecting the whole-brain [2]. In fact, hyposmia is one of the prevalent 
symptoms in early stages of the disease, with several olfactory-related brain areas found severely 
affected in PD patients [3–8]. 
Pathologically, PD is characterized by the degeneration of dopaminergic neurons in the substantia 
nigra pars compacta, and the accumulation of intracellular, proteinaceous inclusions in the surviving 
neurons, known as Lewy bodies (LBs) and Lewy neurites (LNs) [1]. 
According to Braak’s staging theory, the evolution of LB pathology is thought to initiate in either the 
lower brainstem or in the olfactory bulb. Then, as the disease progresses, LB pathology appears in other 
brain areas, including the cerebral cortex, impacting different neural networks and leading to non-motor 
symptoms such as depression, cognitive decline and hallucination episodes [4,9–11]. Defining the 
responsible mechanism for PD pathology progression has challenged the scientific community for 
almost 200 years. During the last decade, the “prion-like” hypothesis has gained particular emphasis 
based on findings from independent experiments in PD patients. In patients that received grafts of normal 
fetal mesencephalic brain tissue, a time-dependent accumulation of LBs and reduced immunostaining 
for dopamine transporter was observed [12–16]. 
Only a minority of PD cases have been linked to genetic factors (less than 10%) with the majority 
being considered sporadic, of unknown origin. Until now, more than 20 genes have been associated with 
PD [17], but this number is expected to increase as new studies including larger number of patients are 
conducted. The first gene linked to familial forms of PD was SNCA, encoding for the protein alpha-synuclein 
(-syn). Thus far, mutations, as well as duplication or triplications of the SNCA gene, are associated with 
familial forms of PD [18–25]. Additionally, recent studies also revealed that polymorphisms in the SNCA 
gene lead to increased risk for developing PD [26–29]. Thus, for all of the above, -syn is regarded as 
one of the major culprits in both genetic and idiopathic forms of PD. 
1.2. Alpha-Synuclein 
-syn is a small 14.5 kDa protein, initially found to be located to pre-synaptic terminals and in the 
cell nucleus [30]. -syn consists of 140 amino acids that can be divided into three domains that confer 
unique properties to the protein. The N-terminal region (residues 1–60) contains several imperfect 
repeats of a consensus motif (KTKEGV). Due to this repeated motif, also found in Apolipoprotein A–I, 
that can form amphipathic alpha-helices upon lipid-binding [31], this region confers membrane binding 
ability to -syn [32,33]. Interestingly, all six PD-related mutations described thus far are located in this 
domain [18–23]. The central region, consisting of residues 61 to 95, is commonly known as the non-A 
component of plaque (NAC) domain. This highly hydrophobic region contains 12 amino acids (71–82) 
essential for -syn filament formation [34]. The last 44 amino acids of -syn confer negative charge to 
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the protein due to abundance of glutamates and aspartates. These negative residues appear to have an 
important effect in modulating -syn aggregation [35] and, in fact, this domain is essential for the 
formation of calcium-mediated annular oligomers via direct binding [36,37]. In addition, the C-terminus 
of -syn has been suggested to play a role on the protein’s chaperone-like activity [38]. 
For years, -syn was regarded as a natively unfolded, monomeric protein. Recently, some studies 
proposed it may occur as a natively folded helical tetramer [39–41], but this subject remains highly 
controversial [42]. Nevertheless, the possibility that -syn occurs naturally in a folded state brought new 
perspectives into the process of its oligomerization and aggregation, one of the major mysteries in the 
field [17]. Major efforts have been placed in understanding which form of -syn acts as the toxic species 
but consensus has not been reached. Currently, it is generally accepted that smaller oligomeric species 
are more toxic than larger aggregated forms [43–45]. However, some authors still claim that the final 
mature aggregates are the most dangerous for cell homeostasis [46,47]. 
-syn is prone to several types of posttranslational modifications (PTMs). Ubiquitination [48–51], 
sumoylation [52–54] and N–terminal acetylation [55–57] have been described. In addition, -syn can be 
phosphorylated [58] in two serines (S129 and S87) and three tyrosines (Y125, Y133 and Y135). It is 
estimated that approximately 90% of the -syn present in LBs is phosphorylated in S129 [59]. Several 
kinases, including CKs, PLKs and GRKs, can phosphorylate -syn on S129 [58,60–65]. Interestingly, 
some of those enzymes were found up-regulated in PD brains [63] or present in LBs [61,66]. S129 
phosphorylation can inhibit -syn fibrillization [67,68], and a similar effect was observed for S87 [69]. 
Unfortunately, the full functional relevance of phosphorylation in both physiological and pathological 
contexts is elusive [70–72]. 
In contrast, nitration of tyrosine residues in -syn (Y39, Y125, Y133, Y136) is known to produce 
toxic effects. In particular, nitrated -syn is present in LBs [73] and nitrated -syn oligomers promote 
mitochondrial impairment and cell death in mammalian cell culture [74]. Furthermore, administration 
of nitrated -syn in the substantia nigra of rats induces severe dopaminergic neuronal cell death, and the 
down-regulation of striatal dopamine and dopamine receptor D2 [75]. Nitration on Y39 blocks -syn 
fibril formation and reduces monomer degradation via the ubiquitin proteasome system [76]. 
Finally, truncated -syn is found in LBs and in animal models and it is thought that some familial  
-syn mutations might promote its truncation [48,77,78]. In vitro, C-terminally truncated -syn enhances 
fibril assembly and induces fibril formation of full-length -syn [79,80]. Nevertheless, the opposite effect 
was reported upon calpain1 or neurosin mediated truncation [81–84]. Interestingly, these two proteases 
cleave -syn near the NAC domain highlighting the importance of this region on -syn aggregation. 
2. Protein Degradation Systems 
Proper protein degradation is a crucial process in intracellular homeostasis and it is ensured by  
two independent, but complementary, systems that work in symbioses. These two pathways, the 
Autopaghy-Lysosomal Pathway (ALP) and the Ubiquitin Proteasome System (UPS), are named upon 
their final destinations, the lysosome and the proteasome, respectively. Monomeric -syn can be actively 
degraded by both organelles [85,86] that compensate each other upon one’s failure [87]. When it comes 
to eliminating higher molecular species, including oligomers and aggregates, the burden shifts to the 
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lysosome [88]. Therefore, and considering the purpose of this review, we will focus specifically on the 
pathways culminating in the lysosomal compartment. 
Autophagy (meaning “self-eating”, in Greek) consists in the process of decomposition and degradation 
of cellular components and organelles via the lysosomal compartment. Autophagy itself serves two main 
purposes: the clearance of deleterious intracellular components, and the recycling of macromolecules 
from functional pre-existing organelles and proteins to guarantee proteome renewal [89]. 
Depending on the cargo delivery method, autophagy can be divided in three main types:  
chaperone-mediated autophagy (CMA), macroautophagy and microautophagy. To our knowledge,  
there is presently no evidence linking -syn to microautophagy. Thus, here we focus only on CMA  
and macroautophagy. 
2.1. -Syn and CMA—A Symbiotic Relation with a “Do not Disturb” Sign 
CMA is a particular cellular mechanism for protein degradation linked to the lysosome. Unlike other 
degradation systems, CMA is based on the recognition of a specific amino acid sequence (KFERQ) [90]. 
This motif is found in nearly 30% of cytoplasmic proteins, including -syn, and in some  
compartment-associated proteins [90]. Protein misfolding, partial folding or PTMs, such as phosphorylation 
and acetylation, can promote or inhibit the CMA pathway [91]. Mechanistically, CMA relies on the proper 
identification and binding of cytosolic Hsc70 (cHsc-70) to the target substrate [92]. This complex is later 
directed to the lysosomal membrane where it interacts with the lysosome-associated membrane protein 
type 2a (LAMP2A) [93,94]. The final step of this translocation process requires the lysosome-associated 
Hsc70 (lHsc70) that targets the substrate to degradation (Figure 1A) [95]. 
The reciprocal interaction between -syn and CMA protein degradation has been of high interest in 
the last decade. Using in vitro purified lysosomes from liver, it was initially described that -syn can be 
actively degraded via CMA and, more interestingly, that two -syn familial mutations, A30P and A53T, 
impair CMA degradation (Figure 1D). Both -syn mutants exhibited higher affinity to the LAMP2A 
receptor, blocking CMA at the LAMP2A level which, ultimately, leads to a full impairment of the 
pathway [85]. Later on, it was shown that -syn can be degraded through this pathway, in several cell 
culture models [96]. In mice, increase of both LAMP2A and Hsc70 levels was observed upon 
overexpression of wild-type (wt) -syn [97]. In a comprehensive study on -syn PTMs, a slight inhibition 
of CMA was observed upon nitration and oxidation (Figure 1B). Furthermore this pathway is stalled 
when -syn is phosphorylated (Figure 1C) or exposed to dopamine. Interestingly, just the latter can also 
completely block the CMA degradation machinery (Figure 1D) [98]. The previous report also proved 
that CMA is only capable of degrading monomers and dimers of -syn, but not oligomers [98]. 
In addition to the direct effect of -syn on CMA, this interplay may also impact other degradation 
pathways. In particular, the A53T -syn mutation can block CMA leading to an activation of 
macroautophagy and an increase of toxicity cultured cells [99]. 
The protective effect of functional CMA on decreasing -syn toxicity and aggregation was confirmed 
in vivo by overexpression of LAMP2A [100]. Furthermore, LAMP2A down-regulation is the main cause 
of decreased CMA activity observed in ageing [101] and, together with Hsc70, it is down-regulated in 
the substantia nigra and amygdala from PD patients [102]. Nevertheless, some studies describe the 
existence of an alternative LAMP2A-independented CMA pathway in fibroblasts [103]. 
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Recently, microRNAs (miRNAs) gained attention also in the context of -syn degradation via CMA. 
Interestingly, miRNAs have been linked to PD [104], and several miRNAs targeting the CMA pathway 
(LAMP2A or Hsc70) have been described. The majority was found to impair -syn degradation and 
potentially alter the aggregation state of the protein [105,106]. In an initial report, four miRNAs were 
found to reduce LAMP2A levels while three others directly down-regulated Hsc70. In all cases an increase 
in -syn was observed. Moreover, these 7 miRNAs were found to be up-regulated in the substantia nigra 
from PD patients [106], correlating with a decrease in both CMA related protein levels. A more recent 
study identified another miRNA, miRNA320a, although it had been previously discarded [105,106]. 
This particular miRNA320a has been linked to a panoply of diseases ranging from fibromyalgia [107] 
to Waldenström macroglobulinemia [108] and more recently to the Ebola virus [109]. 
 
Figure 1. -syn and the CMA. (A) Under physiological conditions, Hsc70 recognizes  
the KFERQ domain of -syn (1) and targets the protein towards the lysosome (2). At the 
lysosomal membrane, -syn interacts with LAMP-2A and promotes its oligomerization (3) 
leading to the entrance of the protein into the lysosome (4). Once inside the lysosome, -syn 
is degraded by proteases (5); (B) PTMs such as oxidation and nitration slightly inhibit this 
pathway and reduce -syn degradation; (C) Phosphorylation of -syn on S129 impairs its 
degradation via CMA. However, while the phosphorylated form of protein does not block 
this pathway (D), dopamine-modified -syn and some familial mutations (A30P and A53T) 
that are also not degraded via CMA, can block this pathway and prevent the degradation of 
other CMA substrates.   
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2.2. Macroautophagy of -Syn—The Last Resource to Avoid Protein Aggregation 
Macroautophagy, commonly referred to as “autophagy”, is the most scrutinized and well known of 
the three autophagic mechanisms. This “content-blind” pathway relies on the formation of de novo double 
membrane-bound vesicles to sequester intracellular components, including whole organelles, towards the 
lysosome [110,111]. This membrane formation mainly relies on the autophagy related protein (Atg) 9, 
both in yeast and humans [112–115]. Macroautophagy is found constitutively active but further activation 
via the mTOR pathway, the mammalian target of rapamycin [116], or the PI3kinase/beclin/vsp34 pathway, 
also known as mTOR-independent pathway, is possible [117]. Autophagosome formation requires two 
ubiquitination steps highly regulated by Atg proteins [118–120]. Initially Atg12 is conjugated with Atg5, 
a process involving Atg7 and Atg10 [121,122]. The Atg12-Atg5 complex is later targeted to the 
autophagosome with Atg16 [123,124]. The second ubiquitination step requires Atg8 (also known by LC3). 
LC3 is C-terminally cleaved by Atg4 to form LC3-I [125,126], which is then conjugated to the lipid 
phosphatidylethanolamine (PE) by Atg7 and Atg3 to generate LC3-II [122,127]. Interestingly, the  
Atg12-Atg5 complex originated from first ubiquitination seems to be necessary for the LC3 processing 
and localization at the autophagosome membrane (Figure 2A) [128,129]. 
Depending on the cargo being degraded, alternative players can be involved in the task. In the case 
of protein aggregates, an alternative has been reported and is usually referred to as aggrephagy. 
Mechanistically, aggrephagy can be divided in two pathways: HDAC6, or BAG-3 mediated. The first 
requires the addition of lysine (K) 63-poliubiquitination chains to the substrate. This can be achieved 
with the involvement of the PD-related protein Parkin [130]. HDAC6 can then recognize the substrate 
and translocate it, in a microtubule-dependent manner, towards the aggregosome [130,131]. Once in the 
aggregosome, the aggregate degradation requires the intervention of p62 and NBR1 that can work 
separately or possibly in a duet, since they can interact [132]. Importantly, both proteins interact with 
PE-LC3, an essential component of the autophagosome membrane [133–135]. Both p62 and NBR1  
also interact with K63-poliubiquitinated chains suggesting that this PTM could be essential for  
HDAC6-mediated aggrephagy [135–137]. 
The second mechanism, mediated by BAG-3, also involves p62 and NBR1, but differs in the initial 
steps of the cascade. The process starts with the “labeling” of the cargo with Hsc70, a reaction that 
requires both BAG-3 and CHIP [138]. Interestingly CHIP has been repetitively associated with -syn 
homeostasis [51,139,140]. This pathway appears to be ubiquitin-independent [138] but, considering that 
the end targets are also p62 and NBR1, it is possible that the substrates are also ubiquitinated along the way. 
Several proteins involved in aggrephagy are common to other cellular mechanisms. In particular, 
HDAC6 has been extensively associated with multivesicular bodies (MVB) and with the delivery of 
their cargo to lysosomes or to the extracellular environment, via exosomes [141]. In any case, we still 
have to understand what directs the proteins towards one of the pathways and, in the future, how this 
can be modulated to enhance the cellular response under stress conditions, such as in the presence of 
protein aggregation. 




Figure 2. -syn and Macroautophagy. (A) Macroautophagy is composed of fine-tuned 
machinery that ensures specific target recognition and cargo delivery to the lysosome;  
(B) Accumulated -syn increases mTor and decreases Atg7 levels, promoting mislocalization 
of Atg9 and leading to impairment of macroautophagy; (C) The -syn familial mutation 
E46K can inhibit macroautophagy via JNK/Blc2, an mTor independent pathway; (D) On the 
other hand, two different effects are associated with the A53T -syn mutation: an increase 
in mitophagy, and accumulation of autophagosomes due to impaired degradation; (E) -syn 
aggregates cannot be degraded by macroautophagy, leading to the impairment of the pathway. 
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-syn degradation via macroautophagy has been mostly studied using specific inhibitors and enhancers 
of this pathway. Both in cell culture or in vivo, wt and mutated -syn can be degraded through 
macroautophagy, a process that may be at least partly modulated by Beclin-1 [142–144]. Furthermore, 
blockade of this pathway generally leads to the accumulation of high molecular weight species of -syn, 
although different macroautophagy inhibitors reveal distinct outcomes [88,96]. Another line of evidence 
indicates that macroautophagy inhibitors affect exclusively mutant A53T -syn, while other studies 
describe different behaviors that vary according to the selected inhibitor [102,145]. In yeast, an organism 
lacking CMA, our group recently demonstrated that -syn phosphorylation on S129 can modulate the 
protein degradation via macroautophagy and, ultimately, inclusion formation [68]. In yeast, it was also 
described that the interplay between phosphorylation and sumoylation has a direct impact on the 
autophagic degradation of -syn [54]. In general, it is believed that macroautophagy is crucial for the 
lysosomal degradation of oligomeric and aggregated -syn, since CMA is unable to handle large protein 
species [98,146]. Once inside the lysosome, -syn is mainly degraded by Cathepsin D (CTSD) [147]. In 
cells, overexpression of an inactive mutant of this aspartyl protease leads to increased -syn levels [148] 
while CTSD knockout mice exhibited accumulation of higher molecular weight -syn species [149]. 
Interestingly, -syn can also have a direct impact on this lysosomal degradation pathway. -syn 
overexpression can inhibit macroautophagy via an interaction with Rab1a that culminates in a mislocalization 
of Atg9 [150]. Furthermore, an increase in mTor and decrease in Atg7 levels has been observed in both 
Dementia with LB (DLB) patients and -syn transgenic mice (Figure 2B) [151]. The same study also 
reported the presence of enlarged autophagosomes and lysosomes, as observed in cells overexpressing 
-syn [142]. In a recent work, -syn aggregates were able to resist macroautophagy leading to a failure 
of the pathway and accumulation of autophagosomes (Figure 2E) [47]. 
In addition to the effects of wt -syn on autophagy, mutations associated with familial forms of PD 
also seem to differentially affect this protein degradation pathway. In the E46K -syn mutant, an impairment 
of autophagy is observed, via inactivation of the JNK1/Blc2 pathway (Figure 2C) [152]. While the A53T 
mutation seems to promote increased mitophagy [153] and the accumulation of autophagosomes due to 
impaired degradation (Figure 2D) [154]. 
In summary, and despite conflicting evidence, it seems unquestionable that there is a strong interplay 
between -syn and autophagy pathways, and that this may enable therapeutic interventions. 
3. Prion-Like Spreading of -Syn Pathology 
For the last decade, it has been postulated that neurodegeneration-related proteins, which are usually 
present in an abnormal aggregated state, can intercellularly transmit their abnormal conformation to 
homotypic native proteins. Here, we focus on the concept of spreading in the context of the overall 
cellular protein homeostasis. In this regard, protein degradation is a key mechanism that undoubtedly 
influences -syn propagation, although its precise modulatory effect is still unclear. 
3.1. Insight from Pathological Studies 
The systematic study of post-mortem human brain tissue from PD patients suggested that -syn 
pathology progresses throughout the brain in a pattern that follows the progression of clinical symptoms. 
This is known as Braak’s staging for PD [4] and is now considered as the first evidence of the hypothesis 
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of the prion-like spreading of -syn pathology. Although Braak’s PD staging could be merely due to the 
differential disease susceptibility among distinct brain regions, the stereotypic pattern and location of 
the zones affected in each stage suggests a spatial-temporal dissemination of the -syn pathology, which 
indeed correlates with cognitive decline [155]. From the first regions affected, the olfactory bulb and 
brainstem, -syn pathology spreads caudo-rostrally to susceptible midbrain regions and to subcortical 
and cortical areas as PD progresses [4]. The initial sites where -syn lesions appear led Braak and co-workers 
to postulate the theory that indeed sporadic -syn pathology is initiated by an exogenous pathogenic 
agent [156,157], although experimental evidence for such agent is still lacking. 
The discovery of LBs in young neurons that were grafted into the brains of PD patients boosted the 
idea of the prion-like spreading of pathology in the brain [15,16]. The grafted cells were obtained from 
human embryos and the transplantation was performed only 11–16 years before the pathological 
examination of the brains, upon death of the patients. Since this period of time is extremely short for -syn 
pathology to spontaneously develop under normal conditions [15,16,158], these findings suggested that 
-syn pathology could be transmitted from diseased to healthy cells. Among the distinct agents and factors 
that could be responsible for transmitting the pathology, the misfolded/aggregated state of -syn was a strong 
contender [159], establishing the basis for the current hypothesis of the prion-like spreading of -syn 
pathology. The -syn that accumulated in the grafted neurons displayed the same characteristics of LBs 
and LNs in the host tissue [160], suggesting a common gradual formation mechanism. In addition, those 
cells were also described to suffer a degenerative process and loss of dopaminergic phenotype [161,162]. 
The presence of LBs in young grafted neurons has been repeatedly confirmed in experiments in rodents 
overexpressing human -syn. In both mice [163] and rats [164,165], the time-dependent transfer of -syn 
from the host to the graft was demonstrated by the presence of human -syn puncta in the transplanted 
cells. In rats, the inclusions formed were described to consist of a core of human -syn surrounded by 
endogenous rat -syn, clearly suggesting a seeding mechanism [164]. 
Another relevant finding was the discovery of -syn in human body fluids, such as cerebrospinal fluid 
(CSF) and blood plasma [166,167]. Taking into account that -syn is traditionally considered a cytoplasmic 
protein, its extracellular presence could be associated to passive release caused by cell death and 
neurodegeneration. However, the similar levels of monomeric -syn found in the CSF and plasma of PD 
and control individuals hinted at a physiological secretion process [166,167]. Unfortunately, there is still 
no consensus on the role of extracellular -syn and whether this is related to pathological conditions. In 
an attempt to clarify this issue, some studies suggest the occurrence of increased levels of the -syn 
oligomeric fraction in the CSF of patients with synucleinopathies [168,169]. 
Overall, these studies indicate that, on one side, there is a fraction of extracellular -syn present in 
physiological conditions and, on the other, that there might be an increase in extracellular -syn 
oligomeric species in diseased individuals. This needs to be further confirmed but requires the 
development of novel and better tools, such as antibodies that recognize specific types of -syn species 
and/or conformers. 
3.2. The Proof of Concept: in Vivo -Syn Propagation Experiments 
The first in vivo -syn propagation studies were performed in host animals already susceptible to an 
age-dependent synucleinopathy. Brain homogenates extracted from symptomatic transgenic mice expressing 
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human A53T -syn triggered an early onset of the pathology with expected clinical and biochemical 
hallmarks, when injected into the brains of young asymptomatic mice [170,171]. The same result was 
obtained when using recombinant human -syn fibrils assembled in vitro [170]. This finding was crucial to 
demonstrate that -syn pathology can be accelerated and spread through the brain after inoculation with 
pathological material. The acceleration of the pathology was interpreted as a seeding effect of the exogenous 
material over the otherwise slow and age-dependent aggregation of the endogenously expressed -syn. 
Subsequent experiments provided additional insight into the process. Injecting recombinant mouse 
-syn fibrils in the dorsal striatum of young wt mice induced pathological -syn transformation leading 
to motor deficits [172]. Similar induction of -syn pathology was described in another study comparing the 
effect of recombinant human -syn and of insoluble brain fractions extracted from DLB patients [173].  
-Syn accumulation was described in several brain regions distant from the injection site, demonstrating 
the propagation capacity of the injected material [172,173]. In addition to the biochemical hallmarks, 
the exogenous induction of -syn pathology also includes a progressive nigrostriatal neurodegeneration 
in the recipient animals as demonstrated by the injection of PD brain extracts into the brains of wt mice [174]. 
Data derived from experiments performed with recombinant protein or with brain-derived pathological 
samples should be interpreted in a complementary way. On one hand, using brain homogenates 
demonstrates that biological protein material is able to induce homotypic pathology in another organism, 
a primary characteristic of prion diseases. On the other hand, experiments using recombinant -syn 
fibrils enable the confirmation that -syn is the major component for pathology induction. Interestingly, 
it was demonstrated that mouse -syn fibrils displayed a higher efficiency in inducing a synucleinopathy 
in wt mice than human -syn fibrils, suggesting the existence of a species barrier effect [173,175]. Finally, 
similar experiments were performed in monkeys injected with LB-fractions derived from sporadic PD 
brains, demonstrating that the induction of a synucleinopathy also occurs in non-human primates and 
that, in the context of propagation of -syn pathology, the monkey-human species barrier is, at best, 
rather soft [174]. 
Despite existing discrepancies regarding the methodologies used in different works [176], and the 
number of open questions that need to be answered [177], the recent studies demonstrate that 
synucleinopathies can be induced by external agents, which raises the issue of whether these neurological 
disorders can also have an infectious origin, even if they do not appear to be contagious.  
3.3. Mechanisms of -Syn Cell-to-Cell Propagation 
Although the prion-like spreading of -syn pathology hypothesis is becoming widely accepted, little 
is still known about the molecular mechanisms underlying this process. It is possible that the mechanisms 
of -syn propagation are probably dependent on the cell type, their physiological state, and the type of 
-syn species transmitted. The various possible mechanisms have been extensively reviewed by many 
in the field [17,178]. 
The spreading of -syn pathology is due to the cell-to-cell transmission of pathological forms of -syn. 
This process requires at least: (i) -syn release from a cell; (ii) -syn uptake by a neighboring cell; and 
(iii) -syn pathology induction in the recipient cell probably caused by seeding of the endogenous  
-syn [178]. The passive release of -syn from dying cells could be a logical possibility, due to the 
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ongoing neurodegenerative process. However, the lack of a clear increase in -syn CSF levels between 
diseased and control individuals [179] limits the likelihood of this process as the main mechanism of release. 
Given the membrane-binding capacity of -syn, another possibility is that secretion might take place 
through an unconventional ER/Golgi-independent secretion pathway [180], or exosome-mediated 
pathway [181,182]. Indeed, the role of exosomes on the spreading of -syn pathology is gaining 
attention, and it was recently shown that exosomes isolated from plasma of PD patients contain higher 
levels of -syn when compared to exosomes from control individuals [183,184].It is also possible that 
exosomal encapsulation of -syn might confer partial protection against extracellular protein degradation 
mechanisms. However, the precise role of exosomes in the spreading of -syn pathology needs to be 
further detailed. 
Other putative mechanisms involved in cell-to-cell transfer of -syn include endocytosis. This was 
confirmed in experiments using dynasore, a potent endocytosis inhibitor that dramatically reduces -syn 
uptake [163]. Nevertheless, no -syn-specific endocytic receptor has been described thus far. Alternative 
intercellular propagation pathways, such as transmission through axonal transport [185], or via a  
trans-synaptic mechanism [186], have been proposed. Importantly, the intracellular trafficking of -syn 
was found to be both anterograde and retrograde [187]. 
Another outstanding issue in the field relates to the factor(s) initiating the transfer and spreading of 
-syn, since -syn is primarily a cytoplasmic protein of which only a small fraction appears to be secreted 
under physiological conditions [180]. Stress conditions, promoting disturbances of cellular proteostasis, 
such as impairment of lysosomal and proteasomal function, and protein misfolding, are associated with 
an increase of -syn release from cells [187]. 
Several factors enhance -syn secretion, including dopamine, which specifically promotes secretion 
of -syn aggregates [188], or the PD-associated Leucine-rich repeat kinase 2 (LRRK2), found not only 
to promote -syn release but also the cell-to-cell transmission process [189]. Importantly, mutations  
in the SNCA gene associated with familial forms of PD also increase -syn secretion from SH-SY5Y 
cells [190,191]. 
Nevertheless, despite recent progress, it seems that we are only at the tip of the iceberg concerning 
the molecular underpinnings of -syn spreading, and much more research needs to be carried out to enable 
a full understanding of the propagation mechanisms and the dissemination of human synucleinopathies 
throughout the nervous system. 
3.4. What Species of -Syn are Transmitted and Spread the Pathology? 
An important feature of prion proteins is that they can adopt different strains, defined as structurally stable 
isoforms of the same polypeptide sequence displaying distinct biochemical and clinical characteristics  
that are associated to the development of pathology in the host organism [192]. Thus, a corollary of  
the prion-like hypothesis for the spreading of -syn pathology is the possible existence of -syn strains. 
Indeed, the broad pathological heterogeneity of synucleinopathies is still an intriguing phenomenon that 
could, perhaps, be explained by the existence of distinct -syn strains. Although this possibility still 
needs to be proved, a recent study demonstrated different proteinase K digestion patterns of -syn 
extracted from brains of individuals who had suffered from different synucleinopathies [175]. Although 
preliminary, this finding establishes the basis for additional research in larger cohorts. 
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-Syn, as most amyloidogenic proteins, can be manipulated in vitro to generate distinct types of aggregates. 
This can be achieved by modulating the self-assembly conditions , by the inclusion of co-factors, such as 
metal ions or lipids , or due to the presence of mutations [190,193–200]. Besides structural differences, a 
prominent hallmark of protein strains is their seeding and self-propagation capacity. In this sense, some 
initial studies about the intercellular transmission of -syn already showed that distinct oligomeric 
species might display distinct seeding and transmission efficiencies [201,202]. In one of the pioneering 
studies, variation of the ionic strength of the assembly buffer resulted in the formation of two distinct -syn 
conformers that displayed distinct physico-chemical properties, self-propagation ability and toxicity [203]. 
Using a different number of iterative seeding cycles, another group described the generation of two 
recombinant -syn species that, despite minor structural variation, exhibited striking differences in 
toxicity and in the cross-seeding ability over tau protein aggregation in cultured neurons. The differential 
tau cross-seeding efficiency of both strains was also confirmed in a mouse model of tau pathology [175]. 
The putative existence of -syn strains might have a relevant impact in the spreading of the pathology, 
since one of the key features of a strain can be its self-propagation ability [203]. A provocative hypothesis 
could be that -syn strains with a more aggressive propagation activity are the ones involved in 
pathology, but isolation of -syn strains from various types of diseased brains is necessary to explore 
this possibility. 
4. Interplay between -Syn Clearance Mechanisms and Spreading 
4.1. Lysosomal Activity and the Generation of Spreading-Competent -Syn Species 
Cellular protein homeostasis is maintained through the combined work of several pathways [204].  
In some instances, it is possible for the cell to compensate for the impairment or failure of one pathway 
through the involvement/recruitment of another. Thus, it is understandable that the majority of data 
gathered thus far suggest an increase of protein release/secretion under autophagic dysfunction. In fact, 
it has been shown that either pharmacological or genetic impairment of autophagy lead to increased -syn 
exocytosis and cell-to-cell transfer, promoting increased cellular toxicity in the cells receiving -syn [205]. 
Furthermore, it was reported that secretion of -syn oligomers via exosomes strongly depends on the 
stability of autophagy [181]. Exosomes originate in MVBs that originate from endosomes using a 
complex lipid and protein machinery, and have now become one of the most intriguing intracellular 
compartments due to the range of putative functions they perform in the cell [206]. Normally, MVBs 
transport their content to the lysosomal compartment. However, upon certain cellular stimuli, MVBs 
form exosomes that will later fuse with the cytoplasmic membrane. MVB membrane proteins have been 
described as crucial players in determining the fate of vesicles. In fact, the PD-associated protein ATP13A2 
is one of those proteins, since its intracellular levels influence the fate of -syn: lysosomal degradation 
or exosomal release [207–209]. An identical paradigm has been postulated for another MVB protein, 
HDAC6, which can also have a role in tau inclusion formation by impairing autophagy [141,210]. 
Furthermore, autophagy induction has been shown to promote fusion of MVBs with the lysosome, and 
inhibit exosomal release [211]. Interestingly, it was recently reported that blockade of macroautophagy 
promotes different secretion mechanisms depending on the -syn molecular species. While small 
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aggregates were secreted in Rab11a-related exosomes, larger aggregates were released in a passive 
method via membrane shredding [212]. 
Impairment of -syn clearance caused by lysosomal dysfunction can be due to enzymatic failure.  
A relevant player of this paradigm is glucocerebrosidade (GCase). This lysosomal hydrolase is associated 
with Gaucher’s disease, the most common lysosomal storage disease (LSD) [213]. It has been shown 
that GCase deficiency leads to neuroinflammation and -syn accumulation [214] and that this depletion 
can also promote -syn intercellular transmission [215]. Interestingly, -syn can inhibit GCase activity, 
thereby enhancing -syn aggregation [216]. Among lysosomal enzymes, CTSD plays a prominent role 
as it is the major enzyme processing -syn in the lysosome (Figure 3A) [147]. Despite the growing 
number of studies devoted to study the role of CTSD in PD and other synucleinopathies, its activity in 
diseased brains has been poorly explored. Initial studies revealed similar activity levels of CTSD in the 
brain and CSF of PD and control individuals [217,218]. However, an exhaustive histochemical analysis 
of individual neurons in the susbtantia nigra of PD revealed a decrease in CSTD staining, compared to 
age-matched controls, particularly in cells containing -syn inclusions [219]. Although the functional 
interpretation of this finding is not trivial, experiments with CTSD deficient animal models provided 
evidence that impairment of CTSD function impairs -syn clearance, leading to its aggregation in 
neurons (Figure 3B) [149,220]. Importantly, CTSD deficiency entails other deleterious consequences, 
including reduction of proteasome activity, which in turn also enhances -syn accumulation, and  
up-regulation of other cathepsins as a compensatory cellular mechanism [220]. Although the increased 
levels of other lysosomal enzymes might, in principle, alleviate -syn aggregation, this does not seem to 
work and might result in a two-edged sword. In this regard, increased cathepsin B (CTSB) levels, 
resulting from CTSD deficiency, display a detrimental activity over -syn aggregates, generating 
fragments with high seeding efficiency that eventually cause the rupture of lysosome, promoting an abrupt 
alteration of the whole cell homeostasis leading to cell death (Figure 3B) [221]. Considering that extracellular 
-syn aggregates can, upon internalization, induce lysosome rupture [222], the putative cleavage of -syn 
by CTSB would create a damaging situation where the cytoplasm would be deficient in lysosomes and 
burdened with -syn seeds and CTSB molecules, which can be active in the cytosol potentially 
amplifying the amount of -syn seeds (Figure 3C) [223]. The eventual cell death caused by lysosomal 
rupture and release of the cytoplasmic content into the extracellular space might induce a pro-inflammatory 
response [222], as well as the spreading of -syn seeds that could trigger a similar process in neighboring 
cells, thereby propagating -syn pathology (Figure 3C–E). 
Moreover, autophagy impairment can take place at an early stage, preventing the proper generation 
of autophagosomes and, therefore, avoiding the confinement of the -syn species that need to be cleared. 
In this case, cytoplasmic proteases come into play, particularly Calpain1, a Ca2+-dependent cytoplasmic 
enzyme that cleaves soluble -syn in several regions, including the NAC region, thus preventing -syn 
self-assembly [81]. On the contrary, Calpain1 activity on aggregated -syn occurs mainly in the C-terminus, 
generating highly amyloidogenic fragments (Figure 3D) [81]. Various studies, including in vivo experiments, 
have widely demonstrated that Calpain1 is able to generate C-terminally truncated -syn fragments that 
are prone to aggregation [82,224,225]. Accordingly, PD midbrain samples show increased activity of 
Calpain1 compared to controls [226] and Calpain1-cleaved -syn species have been detected in LBs 
from the brains of individuals who had PD or DLB [224]. 




Figure 3. Lysosomal dysfunction can promote the release of miscleaved aggregation-prone  
-syn species. (A) Under physiological conditions, CTSD is the main lysosomal enzyme 
clearing -syn. (B) Deficient CTSD function promotes -syn aggregation and lysosomal 
dysregulation, including the up-regulation of other enzymes such as CTSB that can convert 
-syn aggregates into seeding particles able to break and escape from lysosome. (C) Lysosomal 
rupture releases the content of the organelle (e.g., lysosomal enzymes and toxic -syn 
species). (D) These protein particles can be targeted by Calpain1, whose activity, together 
with that of CTSB, also generates -syn propagating species. (E) -syn toxic species can be 
released to the extracellular space by unknown mechanisms or by cell death derived from 
lysosomal rupture and be internalized by surrounding cells. 
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Mouse models of -syn aggregation with decreased Calpain1 activity present a reduced number of  
-syn inclusions and alleviated nigral degeneration and synaptic defects. In addition, Calpain1 inhibition 
also reduces the levels of the astrocytic marker GFAP [225,226], suggesting a possible reduction of the 
inflammatory response. Moreover, antibodies blocking Calpain1-induced -syn truncation prevent the 
intercellular propagation of -syn and neurodegeneration in a mouse model of PD [227]. One possibility 
is that this effect occurs at the extracellular space, where Calpain1 is secreted along with -syn species [227]. 
Considering that -syn accumulation is a known enhancer of Calpain1 secretion [228], one can speculate 
that this vicious cycle contributes to the spreading of -syn pathology and inflammation. In agreement 
with this hypothesis, a relevant relationship between -syn and Ca2+ has also been put forward [229]. Ca2+ 
homeostasis might be strongly affected by -syn, as it was demonstrated that transgenic mice overexpressing 
-syn present long-lasting Ca2+ transients [230]. Ca2+ dysregulation has also been reported to be caused 
by exogenous -syn [231], which promotes Ca2+ influx and, eventually, Calpain activation. Therefore, 
it seems that -syn accumulation is an enhancer of Calpain1 activity and vice-versa, accounting for 
numerous detrimental effects, including -syn pathology and a massive dysregulation of Ca2+ homeostasis. 
Although a comprehensive examination of these data is still necessary, this may suggest a novel 
interpretation of the calpain-cathepsin hypothesis that was put forward in the field of Alzheimer’s  
disease [232,233]—in the case of PD, the final outcome would not only be cell necrosis but also the 
spreading of -syn pathology. 
4.2. Macrosecretion and Lysosome-Mediated Exocytosis 
A recent wave of discoveries brought a new meaning to the interaction between the autophagy and 
secretory pathways, which has been highly neglected in the PD field thus far. 
On one hand, the macroautophagy machinery can regulate an unconventional (ER-to-Golgi independent) 
pathway of extracellular protein secretion, henceforth simply designated as macrosecretion. As previously 
mentioned, parts of the membranes forming the phagosome originate from the ER [234]. It is believed 
that the same process is at the basis of macrosecretion [235]. Although little is known about the 
molecular mechanisms involved, Atg5, GRASP55, and Rab8a were found to be crucial players [236]. 
Thus, autophagy inhibition also leads to macrosecretion blockade, possibly leading to intracellular 
protein accumulation [237]. 
No research has been done so far on the role of macrosecretion in either PD or other synucleinopathies 
but this pathway has already been linked to the intracellular accumulation of Abeta peptide upon 
autophagy impairment [238]. Thus, it would be very interesting to understand (1) what cellular inputs 
push the system towards one of the directions; (2) if -syn can be secreted through this pathway; (3) if 
-syn can also affect macrosecretion; and (4) if inflammation in PD is associated with the release of 
cytokines via macrosecretion (Figure 4A,B). 
Lysosome exocytosis is beneficial in LSDs [239] but its possible role in PD and other synucleinopathies 
has not been analysed. Lysosome exocytosis, an “unconventional secretion pathway”, shares several 
resemblances with synaptic vesicle release, including a Ca2+ dependency [240]. 
Lysosomal exocytosis has been associated with plasma membrane repair and immune  
responses [241,242]. Interestingly, it is regulated by transcription factor EB (TFEB) [239], a protein that 
has also been linked to the clearance of -syn via the lysosome [243]. Thus far, little is known about  
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-syn in this pathway. Since it has been postulated that -syn has an important role in neurotransmitter 
release [244,245], the question is whether it can also modulate lysosome exocytosis, and whether -syn 
can be released to the extracellular environment via lysosome secretion upon autophagy impairment 
(Figure 4C,D). 
 
Figure 4. Macrosecretion and lysosome-mediated exocytosis. (A) Since autophagosomes 
can be secreted to the extracellular space, it is possible that -syn release occurs via this 
pathway, both in normal conditions and upon autophagosome accumulation due to lysosome 
impairment; (B) -syn can alter the levels of important players in macroautophagy and 
eventually play a role in macrosecretion; (C) Lysosomes can fuse with the plasma membrane 
and release their content, a mechanism named lysosome exocytosis. The process is similar 
to the one observed in neurotransmitter release, -syn may play a role; (D) Alternatively, 
impairment of protein degradation might promote the accumulation of high molecular 
weight species of -syn inside the lysosome. One can speculate that, as observed in LSDs, 
the lysosomes might fuse with the plasma membrane and release -syn oligomers and aggregates 
into the extracellular media and start the propagation of pathology. 
4.3. Extracellular -Syn Species 
Among other possibilities extensively reviewed elsewhere [17,178], sources of extracellular -syn 
include (i) exocytosis induced by autophagy dysfunction and (ii) passive release due to pathological 
conditions that eventually lead to cell death. Both possibilities have been demonstrated in different 
cellular and in vivo models, and the most plausible situation is that both take place depending on the cell 
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type, physiological state and -syn species. One important issue, yet unresolved, is the fate and/or the 
physiological role of the -syn species that are present in the extracellular space. The clearance of 
extracellular -syn species can be achieved through proteolysis by extracellular proteases or uptake by 
surrounding cells. The first possibility has been demonstrated in cellular models, and distinct enzymes 
have been found to cleave extracellular -syn. These include neurosin [246], plasmin [247] and matrix 
metalloproteases [248] but the outcome of their activity on -syn-induced toxicity is still debatable.  
The role of these extracellular proteases exceeds the scope of this review and readers are referred to 
other reviews [249]. 
The internalization of -syn species by neighboring cells can be also regarded as a clearing 
mechanism, particularly when microglia are involved [250], although in this case, it may also entail 
opposing effects. As explained above, the internalization of pathological forms of -syn can seed the 
pathogenic conversion of soluble -syn in the receiving cell, and this might be one of the fundamental 
steps for -syn propagation and spreading of pathology (Figure 3E) [178]. This effect has been well 
described in surrounding neurons where new -syn inclusions are formed [185] and in astrocytes where 
-syn can trigger aggregation and an inflammatory response [251]. 
4.4. The Putative Role of Glial Cells in the Spreading of -Syn Pathology 
PD, as other neurodegenerative disorders, is characterized by neuroinflammation in specific brain 
regions [252,253]. This process includes the enrolment of various types of brain cells such as microglia 
and astrocytes [254–256] and the accumulation of different molecules involved in the neuroinflammatory 
response [257]. However, little is known about the precise relationship between -syn pathology and 
neuroinflammation, and its role in disease progression and pathology propagation [258,259]. 
Although -syn is mainly a neuronal protein [260], -syn inclusions can occur in astrocytes and 
oligodendrocytes, in a manner that correlates with nigral degeneration [261,262]. The analysis of PD 
brains showed -syn inclusions in astrocytes with a particular distribution pattern suggesting that 
misfolded or abnormal -syn molecules may escape from damaged terminal axons and then be integrated 
by neighboring astrocytes [263], in agreement with the current hypothesis of prion-like spreading of -syn 
pathology [251]. Likewise, -syn can be taken up by oligodendrocytes [264] and induce the formation 
of cytoplasmic inclusions [265]. In addition to inclusion formation, -syn accumulation might be a 
relevant inducer of the local inflammatory response, as suggested by the addition of exogenous -syn in 
cultured astrocytes and by the analysis of MSA brains, where astrocyte activation was greater in the 
vicinity of -syn inclusions [265]. 
Although microglia activation is also evident in PD [256,266], its precise role in pathology 
progression is yet unknown. On one side, extracellular -syn species are internalized by microglia, 
activating an inflammatory response and contributing to disease spreading [267]. On the other side,  
this phagocytic-like activity of microglia, internalizing -syn, might also be neuroprotective, contributing 
to the clearance of extracellular -syn aggregates [250] and, thereby, stopping -syn propagation.  
This latter property has been successfully exploited to design a therapeutic strategy based on the 
microglial clearance of antibody-targeted extracellular -syn [268]. Microglial phagocytosis of extracellular 
-syn can be mediated by Toll-Like Receptors (TLRs) [269]. Whereas ablation of TLR4 in a mouse 
model of multiple system atrophy resulted in the accumulation of -syn and neuronal loss [270], other 
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studies revealed that TLR2 receptors seem to be specific for oligomeric species of -syn [271].Indeed, -syn 
conformation of appears to be crucial and, since monomeric extracellular -syn enhances microglial 
phagocytosis, aggregated species inhibit this activity [272]. While these observations are still hard to 
reconcile, one can speculate that perhaps aggregated species of -syn might, at some point, hinder the 
intracellular clearance systems, therefore causing glial cells to also contribute to the spreading process. 
5. Conclusions 
The activity of protein clearance mechanisms depends on the physiological state of the cell and its 
surrounding environment. They play a crucial role in clearing misfolded protein species that may appear 
and have deleterious consequences for the cell. The kinetics of protein aggregation, following a 
sigmoidal process, affords biological systems an opportunity to interfere with protein aggregation in the 
early rate-limiting step, thus, protecting the cell from potentially dangerous, aggregation-prone species. 
However, for reasons that are currently still unclear, some proteins may escape the cellular quality 
control systems, misfold, and aggregate, leading to a variety of detrimental consequences, including cell 
death. In some instances, cellular efforts to counteract the protein aggregation process, through the 
activation of protein degradation pathways, might become two-edged swords, enhancing protein aggregation 
and the generation of species that can be transmitted to neighboring cells. 
Although the majority of studies performed thus far have focused on the role of autophagy-lysosomal 
pathway on -syn propagation, it will also be important to assess the role of the UPS in this process, 
since the impairment of this pathway might precipitate a cascade of events culminating in increased 
extracellular release and, thereby, spreading of pathology. Ultimately, we posit that the comprehension 
of the synergistic and compensatory mechanisms of these pathways might lead to the identification of 
novel targets and strategies for modulating the spreading of pathology in PD and other synucleinopathies. 
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